SCYNEXIS Inc (SCYX) stock
SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3072% below fair value
$2.85−0.06 (-2.06%)
Close on Nov 17, 2026Market cap $28.36MP/E –Yield –
Scynexis r&d expenses
Research and development expenses are spending on new products and technology.
Scynexis's R&D Expenses for the twelve months ending Jun 30, 2026 was $26.24M, up 6.4% year over year. For fiscal 2025 it was $22.28M, down 15.6% from the year before. Over ten years it grew 3.1% a year on average. The highest annual figure on record is $38.39M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.28M | -15.6% |
| FY2024 | Dec 31, 2024 | $26.41M | -14.6% |
| FY2023 | Dec 31, 2023 | $30.93M | +13.5% |
| FY2022 | Dec 31, 2022 | $27.26M | +14.7% |
| FY2021 | Dec 31, 2021 | $23.77M | -34.9% |
| FY2020 | Dec 31, 2020 | $36.52M | -4.9% |
| FY2019 | Dec 31, 2019 | $38.39M | +78.1% |
| FY2018 | Dec 31, 2018 | $21.56M | +17.6% |
| FY2017 | Dec 31, 2017 | $18.33M | -8.7% |
| FY2016 | Dec 31, 2016 | $20.08M | +22.1% |
| FY2015 | Dec 31, 2015 | $16.44M | +98.4% |
| FY2014 | Dec 31, 2014 | $8.29M | +89.9% |
| FY2013 | Dec 31, 2013 | $4.36M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.89M | -45.5% |
| Q1 FY2026 | Mar 31, 2026 | $12.35M | +140.2% |
| Q4 FY2025 | Dec 31, 2025 | $4.55M | +5.4% |
| Q3 FY2025 | Sep 30, 2025 | $5.45M | -32.5% |
| Q2 FY2025 | Jun 30, 2025 | $7.14M | +4.9% |
| Q1 FY2025 | Mar 31, 2025 | $5.14M | -28.7% |
| Q4 FY2024 | Dec 31, 2024 | $4.31M | -59.2% |
| Q3 FY2024 | Sep 30, 2024 | $8.07M | +24.9% |
| Q2 FY2024 | Jun 30, 2024 | $6.81M | -3.3% |
| Q1 FY2024 | Mar 31, 2024 | $7.21M | +5.5% |
| Q4 FY2023 | Dec 31, 2023 | $10.59M | +34.9% |
| Q3 FY2023 | Sep 30, 2023 | $6.47M | +0.6% |
| Q2 FY2023 | Jun 30, 2023 | $7.04M | -1.3% |
| Q1 FY2023 | Mar 31, 2023 | $6.84M | +19.2% |
| Q4 FY2022 | Dec 31, 2022 | $7.85M | +2.1% |
| Q3 FY2022 | Sep 30, 2022 | $6.43M | +46.1% |
| Q2 FY2022 | Jun 30, 2022 | $7.13M | +50.6% |
| Q1 FY2022 | Mar 31, 2022 | $5.74M | -17.5% |
| Q4 FY2021 | Dec 31, 2021 | $7.69M | -24.3% |
| Q3 FY2021 | Sep 30, 2021 | $4.40M | -45.2% |
| Q2 FY2021 | Jun 30, 2021 | $4.73M | -44.1% |
| Q1 FY2021 | Mar 31, 2021 | $6.95M | -29.6% |
| Q4 FY2020 | Dec 31, 2020 | $10.16M | -7.3% |
| Q3 FY2020 | Sep 30, 2020 | $8.03M | -13.4% |
| Q2 FY2020 | Jun 30, 2020 | $8.47M | -0.1% |
| Q1 FY2020 | Mar 31, 2020 | $9.87M | +1.9% |
| Q4 FY2019 | Dec 31, 2019 | $10.96M | +63.5% |
| Q3 FY2019 | Sep 30, 2019 | $9.28M | +135.9% |
| Q2 FY2019 | Jun 30, 2019 | $8.47M | +51.3% |
| Q1 FY2019 | Mar 31, 2019 | $9.68M | +81.8% |
| Q4 FY2018 | Dec 31, 2018 | $6.70M | +24.1% |
| Q3 FY2018 | Sep 30, 2018 | $3.93M | -11.8% |
| Q2 FY2018 | Jun 30, 2018 | $5.60M | +25.9% |
| Q1 FY2018 | Mar 31, 2018 | $5.33M | +32.5% |
| Q4 FY2017 | Dec 31, 2017 | $5.40M | +42.7% |
| Q3 FY2017 | Sep 30, 2017 | $4.46M | -8.8% |
| Q2 FY2017 | Jun 30, 2017 | $4.45M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.78M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.89M | – |
See a number that looks wrong?